ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 130 filers reported holding ASCENDIS PHARMA A/S in Q3 2019. The put-call ratio across all filers is 0.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,519,309 | +8.0% | 16,225 | +2.9% | 0.00% | 0.0% |
| Q2 2023 | $1,407,295 | -5.2% | 15,768 | +13.9% | 0.00% | 0.0% |
| Q1 2023 | $1,484,676 | -1.3% | 13,847 | +12.4% | 0.00% | 0.0% |
| Q4 2022 | $1,504,763 | +16.3% | 12,321 | -1.8% | 0.00% | 0.0% |
| Q3 2022 | $1,294,000 | +24.9% | 12,541 | +12.6% | 0.00% | 0.0% |
| Q2 2022 | $1,036,000 | -0.8% | 11,134 | +25.2% | 0.00% | 0.0% |
| Q1 2022 | $1,044,000 | -19.4% | 8,894 | -7.7% | 0.00% | 0.0% |
| Q4 2021 | $1,296,000 | -12.5% | 9,632 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $1,481,000 | +41.5% | 9,293 | +16.9% | 0.00% | 0.0% |
| Q2 2021 | $1,047,000 | +9.5% | 7,950 | +7.2% | 0.00% | 0.0% |
| Q1 2021 | $956,000 | +8.1% | 7,416 | +40.0% | 0.00% | 0.0% |
| Q4 2020 | $884,000 | -3.3% | 5,299 | -10.5% | 0.00% | 0.0% |
| Q3 2020 | $914,000 | +2.0% | 5,922 | -2.4% | 0.00% | 0.0% |
| Q2 2020 | $896,000 | +28.2% | 6,066 | -2.2% | 0.00% | 0.0% |
| Q1 2020 | $699,000 | -13.8% | 6,204 | +6.6% | 0.00% | 0.0% |
| Q4 2019 | $811,000 | +45.1% | 5,822 | +0.2% | 0.00% | 0.0% |
| Q3 2019 | $559,000 | -13.2% | 5,811 | +3.7% | 0.00% | 0.0% |
| Q2 2019 | $644,000 | +51.2% | 5,603 | +54.8% | 0.00% | – |
| Q1 2019 | $426,000 | +5.4% | 3,620 | -43.8% | 0.00% | – |
| Q4 2018 | $404,000 | -15.8% | 6,440 | -4.7% | 0.00% | – |
| Q3 2018 | $480,000 | +37.1% | 6,760 | +28.5% | 0.00% | – |
| Q2 2018 | $350,000 | – | 5,260 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |